New Cancer Immunotherapy Indication for Canadian Patients with Untreated Metastatic Melanoma

KIRKLAND, QC, May 31, 2016 /CNW Telbec/ – Merck (NYSE: MRK), known as MSD outside Canada and the United States, announced today that KEYTRUDA® (pembrolizumab) received approval for the treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab. KEYTRUDA is now the first and only anti-PD1 agent approved for first-line treatment regardless of BRAF mutation status. "We are excited to share this announcement with

CCSN Webinar: Pharma Funding of Patient Groups

Watch this webinar on YouTube!       View the slides on SlideShare!   Pharma funding of patient groups: the building blocks of ethical and appropriate relationships from Canadian Cancer Survivor Network     In this webinar, our panelists explored ethics, transparency, resources, alignment and conflicts in the important relationships between companies and patient groups.    This webinar presented perspectives from subject matter experts from

Host your own Pause for the Cause Coffee Party!

  Step 1: Make some coffee or tea Step 2: Invite colleagues and friends Step 3: Ask friends to donate┬á Download your registration form and inspirational material below!     Coffee Party Inspirations Hold a fancy hat party! Hold a used jewelery sale! Contest to guess the candies in the jar!

CCAN and CADTH/pCODR launch recruitment process for a Health Technology Assessment Patient Engagement Navigator

The Canadian Cancer Action Network (CCAN) and the pan-Canadian Oncology Drug Review (pCODR), a program of the Canadian Agency for Drugs and Technologies in Health (CADTH) are pleased to jointly launch the recruitment process for a Health Technology Assessment (HTA) Patient Engagement Navigator to assist patient groups in understanding the HTA landscape and to provide patient groups with the support required to help optimize the

CADTH Symposium webinar: why is it important, & what now?

Watch the video on YouTube:     View the slides on Slideshare:   CADTH – Why it is important, and what now? from Canadian Cancer Survivor Network Webinar InformationThis webinar featured a round table discussion focusing on the 2016 CADTH Symposium and all the important take-aways for patients & survivors. Featured guests included: – Louise Binder, CCSN Health Policy Consultant, – Mona Forrest, CCSN Board Member, – Sabrina

The Canadian Cancer Clinical Trials Network launches Ask Me Campaign to raise awareness of cancer clinical trials

  TORONTO, May 4, 2016 /CNW/ – Dr. Janet Dancey, Scientific Director of the Canadian Cancer Clinical Trials Network (3CTN) announced today the roll out of a new national campaign to raise awareness of cancer clinical trials in Canada ahead of International Clinical Trials Day on May 20. The Ask Me Campaign will be introduced at more than 60 cancer centres across Canada and include hospital staff wearing "Ask Me" buttons, as well as posters